ALB and chronic myelogenous leukemia, BCR-ABL1 positive: ; only the control cells (211±31%) increased their rigidity (Fig 6C) after AVP stimulation compared with the cells pretreated with AGE-HSA (151±29%) or CML-HSA (82.1±7.8%).